1. Medicines
  2. Oncology
  3. TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Melanoma
  4. Management of Patients with BRAF-Positive Melanoma

Prescribing information

 

Management of Patients with BRAF-Positive Melanoma

   

Helping patients on their TAFINLAR (dabrafenib) + MEKINIST (trametinib) treatment journey

TAFINLAR (dabrafenib) + MEKINIST (trametinib) offers convenient oral dosing twice a day1,2

TAFINLAR + MEKINIST is an oral targeted combination therapy for adults with BRAF V600-positive metastatic or unresectable melanoma, and for the adjuvant treatment of patients with BRAF V600-positive Stage III melanoma, after complete resection.1,2

TAFINLAR + MEKINIST offers convenient oral dosing twice a day. It is the only oral option in the adjuvant setting and offers the lowest pill burden in the metastatic setting.1–4 Dosing is the same for both adjuvant and metastatic treatment settings.1,2

Please select an option below to find out more about patient management, dosing and administration, and managing side effects.

References

  1. TAFINLAR (dabrafenib) Summary of Product Characteristics.
  2. MEKINIST (trametinib) Summary of Product Characteristics.
  3. BRAFTOVI (encorafenib) Summary of Product Characteristics.
  4. MEKTOVI (binimetinib) Summary of Product Characteristics.

 

Rate this content: 
No votes yet
UK | December 2021 | 122583-1
Oncology
Article

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]